It may be possible to improve performance of ER subtyping for lower tumor fraction samples with additional sequencing depth, using TFBSs identified directly from ER + /− tumors, or joint analysis of multiple cfDNA timepoints from the same patient. The gene discussed is ESR1; the disease is neoplasm.